Diastolische Herzinsuffizienz – Herzinsuffizienz mit erhaltener Ejektionsfraktion

Als „diastolische Herzinsuffizienz“ auf myokardialer Ebene im klinischen Alltag wird die Herzinsuffizienz mit erhaltener Ejektionsfraktion verstanden (HFpEF). Die Diagnosestellung ist herausfordernd und setzt ein gutes Verständnis von Pathophysiologie und Hämodynamik voraus. Die Therapieoptionen unterscheiden sich fundamental vom etablierten Vorgehen bei Herzinsuffizienz mit systolischer linksventrikulärer Dysfunktion und sind häufig limitiert.

Schlüsselwörter

Herzinsuffizienz - Ejektionsfraktion - Linksherzinsuffizienz - Diagnostik - H2FPEF-Score - Therapie

• Literatur

• 1 McDonagh TA, Metra M, Adamo M. ESC Scientific Document Group. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42: 3599-3726
• 2 McDonagh TA, Metra M, Adamo M. ESC Scientific Document Group. et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2023; 44: 3627-3639
• 3 Savarese G, Becher PM, Lund LH. et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res 2022; 118: 3272-3287
• 4 Tsao CW, Aday AW, Almarzooq ZI. et al. Heart disease and stroke statistics–2022 update: a report from the American Heart Association. Circulation 2022; 145: e153-e639
• 5 Borlaug BA, Lam CS, Roger VL. et al. Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol 2009; 54: 410-418
• 6 Paulus WJ, Zile MR. From systemic inflammation to myocardial fibrosis: the heart failure with preserved ejection fraction paradigm revisited. Circ Res 2021; 128: 1451-1467
• 7 Anjan VY, Loftus TM, Burke MA. et al. Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction. Am J Cardiol 2012; 110: 870-876
• 8 Obokata M, Reddy YNV, Pislaru SV. et al. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation 2017; 136: 6-19
• 9 Heidenreich PA, Bozkurt B, Aguilar D. et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022; 145: e895-e1032
• 10 Reddy YNV, Carter RE, Obokata M. et al. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation 2018; 138: 861-870
• 11 Reddy YNV, Kaye DM, Handoko ML. et al. Diagnosis of heart failure with preserved ejection fraction among patients with unexplained dyspnea. JAMA Cardiol 2022; 7: 891-899
• 12 Edelmann F, Wachter R, Schmidt AG. et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF Investigators. JAMA 2013; 309: 781-791
• 13 Redfield MM, Chen HH, Borlaug BA. et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013; 309: 1268-1277
• 14 Teerlink J, Cotter G, Davison BA. et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013; 381: 29-39
• 15 McMurray JV, Adamopoulos S, Anker SD. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 2012; 33: 1787-1847
• 16 Edelmann F, Gelbrich G, Duengen HD. et al. Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the ex-DHF pilot study. J Am Coll Cardiol 2011; 58: 1780-1791
• 17 Anker SD, Butler J, Filippato G. EMPEROR-Preserved Trial Investigators. et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021; 385: 1451-1461
• 18 Solomon SD, McMurray JJV, Claggett B. DELIVER Trial Committees and Investigators. et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2022; 387: 1089-1098
• 19 Nassif ME, Windsor SL, Borlaug BA. et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med 2021; 27: 1954-1960